Expertise in
17
conditions

Dr. Luke Nordquist

Oncology
The Urology Cancer Center
17607 Gold Plz, 
Omaha, NE 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Expertise in
17
conditions
The Urology Cancer Center
17607 Gold Plz, 
Omaha, NE 

Overview

Luke Nordquist is an Oncologist practicing medicine in Omaha, Nebraska.

Dr. Nordquist is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, and Prostatectomy.

He is actively involved in clinical research, co-authoring 34 peer reviewed articles and participating in 25 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in NE

Hospital Affiliations

The Nebraska Methodist Hospital
Chi Health Lakeside

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 5 Less Insurance Carriers -

Locations

The Urology Cancer Center
17607 Gold Plz, Omaha, NE 68130

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: March 16, 2026
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
Enrollment Status: Recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drug: Abiraterone Decanoate
Study Phase: Phase 1
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drug: ARX517 Anti-PSMA AS269-Conjugated Monoclonal Antibody
Study Phase: Phase 1
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 23, 2026
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2026
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: Apalutamide, Abiraterone, Docetaxel, Prednisone
Study Phase: Phase 1
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
View 8 Less Clinical Trials

34 Total Publications

Reply by Authors.
Reply by Authors.
Journal: The Journal of urology
Published: February 06, 2026
Similar Doctors
Expertise in
42
conditions
Dr. Nicole Shonka
Oncology
Expertise in
42
conditions
Dr. Nicole Shonka
Oncology

Fred & Pamela Buffett Cancer Center-Nebraska Medical Center

505 S 45th St, 
Omaha, NE 
 (2.9 miles away)
402-559-5600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nicole Shonka is an Oncologist practicing medicine in Omaha, Nebraska. Dr. Shonka is highly rated in 42 conditions, according to our data. Her clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Expertise in
25
conditions
Dr. Robert G. Bociek
Oncology
Expertise in
25
conditions
Dr. Robert G. Bociek
Oncology

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (2.9 miles away)
402-559-5600
Experience:
38+ years
Languages Spoken:
English
See accepted insurances

Robert Bociek is an Oncologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 38 years. Dr. Bociek is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
59
conditions
Dr. Margaret Block
Oncology
Expertise in
59
conditions
Dr. Margaret Block
Oncology

Oncology Hematology West PC

17201 Wright St, Suite 200, 
Omaha, NE 
 (7.9 miles away)
402-334-4773
Experience:
50+ years
Languages Spoken:
English
See accepted insurances

Margaret Block is an Oncologist practicing medicine in Omaha, Nebraska. She has been practicing medicine for over 50 years. Dr. Block is highly rated in 59 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, HER-2 Positive Breast Cancer, and Inflammatory Breast Cancer.

Frequently Asked Questions about Dr. Luke Nordquist

How do I make an appointment with Dr. Luke Nordquist?

You can book an appointment with Dr. Luke Nordquist by calling their office at 402-991-8468. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Luke Nordquist a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Luke Nordquist is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Luke Nordquist specialize in?

While Dr. Luke Nordquist is a Oncology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Renal Cell Carcinoma (RCC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Luke Nordquist participate in research or clinical trials?

Yes. Dr. Luke Nordquist has published 34 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Luke Nordquist's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Luke Nordquist accept my insurance?

Dr. Luke Nordquist accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 402-991-8468 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nordquist's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 7 Advanced Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile